A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer
Status:
Withdrawn
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
We hypothesize that administration of LDE-225 in humans with pancreatic cancer will result in
inhibition of paracrine HH signaling in the pancreatic tumor stroma while having no effect on
autocrine signaling in the tumor cell compartment. Furthermore we hypothesize that treatment
with LDE-225 will result in changes in the tumor stroma (decreased desmoplasia, increased
vascularity) that will result in improved tumor blood flow.
The purpose of this study is to determine if, where and how LDE-225 works in pancreatic
cancer. A cancer cell's growth can depend on the cells and tissue around it. The cells and
tissue make chemical signals to influence the cancer's growth. This research study is
evaluating LDE-225 designed to interfere with one of the growth signals causing pancreatic
cancer growth.
Phase:
Early Phase 1
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborators:
National Cancer Institute (NCI) Novartis Pharmaceuticals Rutgers Cancer Institute of New Jersey